Purpose: The preoperative determination of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), and Ki-67 expression status is crucial because these factors influence the therapeutic response to endocrine therapy, chemotherapy, and HER2-targeted therapy and help in the selection of adjuvant or neoadjuvant treatment. To evaluate the accuracy of core needle biopsy (CNB) in determining ER, PR, and HER2 status, and Ki-67 level status, we compared the results of CNB with those of surgical specimens. Methods: We retrospectively reviewed data from 191 patients with breast cancer whose ER, PR, and HER2 status, and Ki-67 level status was analyzed using both CNB and surgical specimens between 2013 and 2015. Patients who received neoadjuvant chemotherapy were excluded from this study. ER, PR, and Ki-67 were detected using immunohistochemistry (IHC) and reported as the percentage of positively stained cells. The cutoff point was 1% for ER and PR, and 14% for Ki-67. HER2 was determined by IHC and/or fluorescence in situ hybridization (FISH). HER2 positivity was defined as IHC 3+ or FISH (+). Results: In correlation analysis, Pearson correlation coefficients were 0.950 for ER expression, 0.813 for PR expression, 0.847 for HER2 grade, and 0.817 for Ki-67 expression level (p< 0.0001). According to criteria for ER, PR, HER2, and Ki-67, the sensitivities of ER, PR, HER2, and Ki-67 assessment in CNB were 92.6%, 88.8%, 100%, and 80.6%, respectively. The specificities of ER, PR, HER2, and Ki-67 assessments in CNB were 90.7%, 86.0%, 99.1%, and 88.7%, respectively. Conclusion: The ER, PR, HER2, and Ki-67 status in CNB specimens correlated well with their status in surgical specimens. The HER2 status was the most accurately assessed factor in CNB specimens when compared to its assessment in surgical specimens. However, Ki-67 levels in CNB specimens were lower than those in surgical specimens.
INTRODUCTION
Different breast cancer subtypes, determined on the basis of gene expression patterns derived from microarray analysis, are associated with significantly different survival and recurrence rates [1, 2] . However, because of the cost and time constraints, gene expression cannot be evaluated in every breast cancer patient. Therefore, a simplified classification based on immunohistochemical (IHC) analysis of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) has been adopted in clinical practice [3] . Recently, the importance of proliferation indicators such as has been emphasized because several studies revealed that the Ki-67 level was associated with treatment response and survival after neoad-juvant treatment [4, 5] . According to the St. Gallen International Expert Consensus on the primary therapy of early breast cancer, microarray molecular subgroup classification based on IHC analysis of ER, PR, HER2, and Ki-67 provides powerful prognostic information [3, 6] . Although surgical specimens collected after breast cancer surgery provide the most reliable results for IHC evaluation of ER, PR, HER2, and Ki-67, IHC analysis of core needle biopsy (CNB) specimens is required in certain cases.
When patients with locally advanced breast cancer are considered for neoadjuvant treatment, therapeutic strategies are based on the results of IHC analysis of CNB specimens. In addition, when distant metastasis occurs after primary breast cancer treatment, it is crucial to assess the ER, PR, HER2, and Ki-67 statuses and histologically evaluate the metastatic lesions because the ER, PR, and HER2 statuses of
METHODS

Patients
We reviewed the medical records of patients who underwent breast 
Pathological assessment
CNB specimens were retrieved from tumor centers by using an ultrasonography-guided 14-gauge Tru-Cut needle. All immunostaining procedures and subsequent interpretations were performed at our institution. Specimen slides of patients who had undergone CNB at other clinics were reviewed again at our institution. In case of missing IHC results, additional staining and review processes were performed.
The pathology results were interpreted by a senior pathologist with abundant experience in evaluating breast cancer biopsies.
IHC analysis was performed to evaluate the expression of ER, PR, HER2, and Ki-67 in CNB and surgical specimens. ER and PR expression was calculated as a percentage of cells showing definite nuclear staining for ER and PR. The cutoff value for ER and PR positivity was ≥1% of tumor cells positive for nuclear staining. HER2 expression was assessed on a scale from 0 to 3+ according to the intensity of cell membrane staining. Specimens were considered HER2-positive either when the IHC score was 3+ or when HER2 gene amplification was identified by fluorescence in situ hybridization (FISH) [11] . Ki-67 expression was measured using a rabbit monoclonal antibody as previously described, and expressed as a percentage of immunohistochemically stained cells relative to the total number of counted cells [12] . The cutoff value for Ki-67 positivity was ≥15% of the cells positive for staining.
Statistical analysis
Patient characteristics are presented descriptively as percentages.
Pearson correlation coefficient was used to assess the correlation be- 
RESULTS
A total of 191 patients were included in this study. The patient characteristics are summarized in Table 1 HER2 status was assessed in 152 patients because samples were not available and HER2 assessment was unnecessary in DCIS or very small tumors in invasive breast cancer. Among 23 patients whose HER2 was 2+ on IHC, four showed HER2 gene amplification in FISH and were thereby categorized as HER2-positive. CNB specimens from 37 patients (24.3%) and surgical specimens from 36 patients (23.7%) were HER2-positive. There was only one discordant case, which was positive in the CNB specimen but negative in the corresponding surgical specimen. The sensitivity and specificity of HER2 in CNB specimens were 100% and 99.1%, respectively. The PPV and NPV of HER2 in CNB specimens were 97.3% and 100%, respectively (Table 3) .
DISCUSSION
CNB is a standard diagnostic procedure conducted in patients with suspected breast cancer. Although the histopathological diagnosis of breast cancer from CNB specimens is of prime importance, IHC evaluation of biomarkers such as ER, PR, HER2, and Ki-67 offers additional information that helps determine the optimal therapeutic regi-men. Our results showed high concordance rates between the results from CNB and surgical specimens: 92.2%, 88.0%, 99.3%, and 83.8%
for ER, PR, HER2, and Ki-67 expression, respectively. The ER positivity rate was higher in CNB specimens than in surgical specimens, which is consistent with the results of a previous study [9] .
The concordance rate of ER expression was slightly higher than that of PR, which was consistent with previous reports [10, 13, 14] . The distribution of PR in tumors is more heterogeneous than that of ER [9, 15] . Studies using both IHC and FISH to evaluate HER2 status had higher concordance rates than those using IHC alone [10, 16, 17] . We tried to perform additional FISH tests in 2+ cases and evaluate HER2 amplification. However, because of time and cost constraints, most patients with HER2 2+ results did not undergo FISH tests. In our study population, the positivity rate of HER2 was 24.3% in CNB specimens and 23.7% in surgical specimens, which was slightly higher than the rates reported in previous studies [14] .
In this study, the concordance rate for Ki-67 was lower than that for other biomarkers, indicating that Ki-67 is more heterogeneously distributed [14] . The concordance rates of Ki-67 were similar when the Ki-67 expression cutoff values were 14% and 20% (82.4% and 81.3%, respectively). There was an increase in Ki-67 expression after CNB.
Tagliabue et al. [18] have suggested that the post-CNB increase in the expression of Ki-67, a well-known predictive marker for tumor proliferation, might be related to the wound healing process. An increase in Ki-67 expression has been reported in specific breast cancer molecular subtypes: HER2-positive and triple negative tumors [18, 19] .
More than 30 single-center studies have compared the predictive validity of percutaneous diagnostic biopsies to that of surgical specimens in determining histologic type and other biomarkers [9,10,13- Data are presented as percentage (%). ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; PPV = positive predictive value; NPV = negative predictive value.
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Hee Ju Sohn, et al. 17, 20, 21] . Although the concordance rates did vary among these studies, their results consistently indicated that preoperative determination with CNB has a high concordance rate. Some of these studies compared ER expression alone, whereas some included ER, PR, and HER2 [9, 10, 13, 14, 17, 21, 22] . Chen et al. [23] performed a meta-analysis of 27 studies and concluded that CNB has high concordance rates with excisional biopsy. The included studies had different sample sizes, sample number of biopsies, cutoff value of positivity, and technical differences in biopsy procedures and staining.
Several explanations have been proposed previously for the discordance between the results of CNB and those of surgical specimens.
First, because cancer has a heterogeneous character, the core does not represent the entire tumor [22] . Factors related to intratumoral heterogeneity, such as larger tumor size, axillary lymph node involvement, younger patient age, and lower grade of tumor, have been shown to contribute to a higher discordance in the results [16, 21, 24] . Second, proper formalin fixation is essential for evaluating IHC status. An increase in the duration of formalin fixation is associated with an increase in the number of false-negative results and a sample fixation time of less than 24 hours is recommended [16, 25] . We attempted to limit the fixation time to less than 12 hours for samples retrieved from our institution. However, any technical errors during the entire process can affect the results of IHC status.
Adjuvant chemotherapy, which is widely used in breast cancer treatment, has the advantages of lower cancer recurrence and improved overall survival [26] . Application of endocrine therapy is also increasing because it offers the benefits of safety and ease of administration [27] . In HER2-positive cancers, which are known for unfavorable prognoses, the anti-HER2/neu receptor antagonist trastuzumab improves disease-free survival and overall survival [28] . However, as trastuzumab has no benefits in HER2-negative breast cancers, a care- Third, the CNB-based diagnosis of some patients was performed at local clinics. Although we performed an additional review of the slides at our hospital and checked the IHC status, the staining protocols used at these clinics and our institution might have been different.
We conclude that, compared with surgical specimens, CNB has high diagnostic accuracy in evaluating ER, PR, HER2, and Ki-67 status. Our findings support the recommendation that CNB should be considered as the initial procedure for assessment of receptor status in breast cancers.
